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SUMMARY – Stress urinary incontinence (SUI) continues to present a major complication after 
radical prostatectomy. Suburethral slings represent one of the less invasive options for postprostatec-
tomy SUI, and a more recent addition is a transobturator sling, the AdVance®. We report our results 
with the AdVance® sling for the management of postoperative SUI. Th e evaluation was conducted on 
47 patients with AdVance® implant for SUI in our institution (November 2010 - June 2017). Mea-
surements included age, etiology of SUI, duration of SUI, follow-up and pad use per day (PPD) pre- 
and postoperatively. Patients were classifi ed as cured if they used no pads or 1 PPD for security 
 reasons, or as improved if 1-2 PPDs were used and if there was a 50% reduction in pad use per day 
postoperatively. In our series we observed a reduction of mean PPD of 5.1 (2-8) to 1.7 (0-4) postop-
eratively. After follow-up and according to our criteria, the cure rate was 51.1% (24/47) and the im-
provement rate 27.5% (13/47). Th e overall success rate was 78.6% (37/47). No improvement was 
 observed in 21.4% (10/47) of patients. Failure rates after sling placement for patients with additional 
treatments following prostatectomy were much higher (60% (3/10) for radiation therapy and 66.7% 
(4/10) for urethral stricture disease). Our results show favourable cure and improvement rates and are 
comparable to results from larger series. Th e most appropriate candidates for the AdVance® sling are 
patients with mild to moderate postprostatectomy SUI. Th e results may be even better in patients 
without additional treatment following prostatectomy, such as radiation therapy or surgery for stric-
ture disease.
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Introduction
Th e incidence of organ confi ned prostate cancer 
has increased in our country and worldwide over the 
past few decades as a result of the widespread applica-
tion of PSA testing and increased life expectancy1,2,3. 
Due to an increased number of performed radical 
prostatectomies (RP) for localized disease, an increas-
ing number of men have postoperative stress urinary 
incontinence (SUI) that continues to present a major 
complication, despite improvements in surgical tech-
nique3-5. Th e reported incidence rate of postoperative 
SUI varies widely between 5% and 65%4-7.
Treatment options for early postprostatectomy 
SUI begin with conservative approaches, such as anti-
cholynergics, physiotherapy, electrostimulation and 
biofeedback for the fi rst year after RP before moving 
on to surgical therapy5,6. After failed conservative 
treatment, two major treatment options for male SUI 
are the artifi cial urinary sphincter (AUS) and the male 
sling4,5. Th e AUS has a high success rate of about 79% 
and is considered to be the gold standard for the treat-
ment of postprostatectomy incontinence4,5.
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Suburethral slings represent one of the less invasive 
options for postprostatectomy SUI, and a more recent 
addition is the transobturator sling (TOT), the Ad-
Vance®8,9. In contrast to AUS and other slings that 
work through direct compression of the urethra, the 
TOT AdVance® sling functions by repositioning and 
lengthening of the functional sphincteric urethra. It 
off ers a new functional non-compressive approach 
without any moving mechanical parts8-10.
Th e purpose of this report is to evaluate clinical 
outcomes after the placement of the AdVance® TOT 
sling in men with postprostatectomy SUI at our insti-
tution. Th e surgical technique of sling placement is 
also described herein.
Patients and methods
Our study was conducted in a retrospective manner 
(November 2010 - June 2017) and involved 47 male 
patients with SUI caused by radical retropubic prosta-
tectomy (38/47), radical laparoscopic prostatectomy 
(2/47), transvesical adenomectomy (2/47), or transure-
thral resection of the prostate (TURP) (5/47). All pa-
tients were continent prior to prostate surgery. Mea-
surements included age, etiology of SUI, duration of 
SUI and follow-up. Incontinence was assessed on the 
basis of pad per day use.
Prior to AdVance® sling implantation, all patients 
were evaluated with full medical history, physical ex-
amination and urinalysis. Dynamic urethrocystoscopy 
was performed on each patient in dorsal lithotomy po-
sition under local anesthesia (lidocaine gel) to evaluate 
the functionality of sphincteric urethra and to exclude 
urethral stricture disease or bladder neck sclerosis. 
Gentle pressure was applied to the midperineum dor-
sal to the level of the membranous urethra during ure-
throscopy to evaluate the mobility and coaptation of 
the sphincteric mechanism. Patients with evidence of 
prostate carcinoma relapse, urethral scarring, bladder 
neck contracture, urethral strictures and neurogenic 
causes of incontinence were excluded. Urodynamic 
studies were not performed. Th e time interval between 
prostatectomy and the placement of the sling had to 
exceed 6 months.
Th e AdVance® sling (American Medical Systems, 
Minnetonka, MN, USA) placement was performed 
under spinal anesthesia in dorsal lithotomy position, as 
described by Rehder and Gozzi8. Th e operative steps 
for the AdVance® sling placement are shown in Fig-
ures 1-6. A single dose of perioperative antibiotics was 
administered, comprising Metronidasole and 3rd gen-
eration cephalosporine. Catheters were removed on 
the 2nd postoperative day with subsequent measuring 
of residual urine by ultrasound, followed by hospital 
discharge on the next day.
Th e degree of pre- and postoperative SUI was eval-
uated by the number of pads used per day (PPD). Pa-
tients were monitored after AdVance® sling implanta-
tion and daily pad usage was evaluated by personal 
interview. According to the classifi cation of inconti-
nence by International Continence Society (ICS), SUI 
Fig. 1. After the placement of a Foley urethral catheter, 
the urethral bulb and corpus spongiosum are mobilized 
and prepared; the trocar passer insertion site is marked 
with a spinal needle 2 cm below the adductor longus 
muscle tendon insertion.
Fig. 2. Th e helical needle passer is advanced through 
the medial aspect of the obturator foramen.
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was defi ned as either mild (use of 1 or 2 PPD), moder-
ate (use of 3 or 4 PPD) or severe (use of more than 4 
PPD)11. As previously reported by Bauer et al.12, pa-
tients were classifi ed as cured if they used no pads or 1 
PPD for security reasons, or as improved if 1-2 PPD 
were used and if there was a 50% reduction in daily 
pad usage. Otherwise, they were classifi ed as not im-
proved or failed. Treatment was considered a success if 
patients were either cured or improved.
Results
Between November 2010 and June 2017, the Ad-
Vance® sling was implanted in 47 patients in our insti-
tution. Mean age at the time of the surgery was 68 
years (range: 47 - 78) and mean duration of inconti-
nence was 41.6 months (range: 12 - 132).
Etiology of SUI was radical prostatectomy (85.1%), 
transvesical adenomectomy (4.3%) and TURP (10.6%). 
Median follow-up was 53 months (range: 2-81). All 
patients attempted pelvic fl oor exercises and received 
anticholinergics to improve continence status prior to 
the AdVance® sling implantation. Radiation therapy 
for disease relapse preceded sling placement in 5 
 patients (10.6%). Six patients (12.8%) were treated en-
doscopically for postprostatectomy urethral stricture 
disease or bladder neck sclerosis prior to sling place-
ment.
Fig. 3. Th e needle passer is exiting at the apex of the angle 
between the corpus spongiosum and inferior pubic ramus. 
Th e mesh is secured to the needle tip and brought back 
through the stab incision.
Fig. 4. Th e mesh is brought back with the needle passers 
through the stab incisions bilaterally.
Fig. 5. Sutures are used to fi x the central portion 
of the mesh to the corpus spongiosum.
Fig. 6. Pulling fi rmly on the sling arms tensions the sling. 
Following the tensioning of the sling, approximately 2-4 
cm of proximal urethral movement is observed. Th e sling 
provides support to the dorsal distal portion of the 
membranous urethra, which acts as a backstop during 
stress.
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Th e number of pads used per day preoperatively 
and postoperatively, in accordance with the classifi ca-
tion of incontinence by International Continence So-
ciety (ICS), is shown in Table 111. According to ICS 
criteria, preoperatively 0%, 36.8% and 63.2% of our 
patients were using no pads, 1-4 PPD, and >4 PPD, 
respectively. Postoperatively 31.6% of the patients 
were using no pads, 57.9% were using 1-4 PPD and 
only 10.5% were using >4 PPD. In our series we ob-
served a signifi cant reduction of mean preoperative 
PPD usage of 5.1 (range: 2-8) to 1.7 (range: 0-4) post-
operatively.
Th e results following an AdVance® sling implanta-
tion in 47 men with SUI comparing groups of patients 
with or without additional postprostatectomy inter-
ventions is shown in Table 2. After follow-up and ac-
cording to our criteria, the cure rate was 51.1% (24/47) 
and the improvement rate 27.5% (13/47). Th e overall 
success rate was 78.6% (37/47). No improvement was 
observed in 21.4% (10/47) of patients. Clinical condi-
tions of these patients did not improve after surgery; 
however, there was no worsening when compared to 
the pad use before AdVance® sling implantation. Fail-
ure rates for patients with additional treatments after 
prostatectomy were much higher (60% (3/5) for radia-
tion therapy and 66.7% (4/6) for internal urethrotomy 
group). Cure and improvement rates following sling 
implantation for patients without additional treat-
ments after prostate surgery were 61.1% (22/36) and 
30.6% (11/36) respectively, resulting in a 91.7% 
(33/36) success rate.
Th ere were no intraoperative complications. Th e 
overall early postoperative complication rate after sling 
placement was 6.4% (3/47). Two patients had postop-
erative wound infections and one had passing urinary 
retention one week after catheter placement. No ero-
sion of the urethra was observed, and no episodes of 
sling infections, erosions or explantations were noted 
during the study period.
Discussion
Despite improvements in surgical technique and 
technological developments in laparoscopy and robot-
ics, SUI continues to present a major complication fol-
lowing RP. Over recent decades, SUI rates have been 
decreasing due to modifi ed surgical techniques, but 
remain at 1–2% one year after RP, even in high-vol-
ume centers of excellence4. Following failed conserva-
tive treatment 1 year after RP, surgical therapy for SUI 
is recommended5.
Th e AUS (AMS 800, American Medical Systems, 
Minnetonka, MN, USA) was introduced in 1971 with 
high continence and patient satisfaction rates. It re-
mains the gold standard for the surgical treatment of 
severe persistent postoperative SUI and total inconti-
nence4,5,13. Success rates after AUS implantation are 
still the highest when compared to all other treatment 
options and devices on the market13,14. Unfortunately, 
Table 1. Pre- and postoperative pad usage after AdVance® 
sling implantation in 47 men with postprostatectomy 
SUI 
ICS defi nition






(>4 PPD) 30 (63.8%) 7 (15%)
Mild/moderate SUI
(1-4 PPD) 17 (36.2%) 20 (42.5%)
Continent SUI
(0 PPD) 0 (0%) 20 (42.5%)
Table 2. Results after AdVance® sling implantation in 47 men with SUI, comparing groups 
of patients with or without additional postprostatectomy interventions 
N (%)
Cure Improvement Failure Success
Prostatectomy only 22 (61.1) 11 (30.6) 3 (8.3) 33 (91.7)
Prostatectomy & radiation 
therapy 0 2 (40) 3 (60) 2 (40)
Prostatectomy & urethral 
stricture surgery 2 (33.3) 0 4 (66.7) 2 (33.3)
TOTAL 24 (51.1) 13 (27.5) 10 (21.4) 37 (78.6)
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there is a signifi cant reoperation rate (>35%) after 10 
years in patients with AUS due to mechanical failure14. 
On the other hand, some patients do not have the abil-
ity or the motivation to operate the pump used with an 
AUS. In the late 1990s, male slings were introduced as 
an alternative to AUS for patients with mild to moder-
ate incontinence. Th e main advantage of slings com-
pared to the AUS is minimally invasive approach with 
short learning curve and the lack of mechanical com-
ponents, with reduced the potential for device failure.
In 2007, Rehder and Gozzi8 from Innsbruck (Aus-
tria) published the results of the fi rst TOT sling sus-
pension technique in the treatment of male postopera-
tive SUI. Th e AdVance® sling is self-anchored with 
bilateral polypropylene mesh arms placed in a TOT 
fashion. It is implanted using a TOT approach via a 
median perineal incision using helical trocar needles. 
Rocco et al.15 published that SUI after RP results from 
the shortening of anatomical and functional sphincter 
length due to postoperative prolapse of the urethral 
sphincter complex. Th e AdVance® sling supports that 
dorsal structure of the membranous urethra and 
achieves passive continence through subsequent eleva-
tion, lengthening and repositioning of the descended 
sphincter segment8-10. In contrast to retropubic and 
bone-anchored compressive devices, the force is ap-
plied parallel to the urethral lumen8. Th e sling aug-
ments the lax and descended dorsal support structures 
of the sphincter and off ers a non-obstructive and func-
tional therapeutic approach for the treatment of post-
prostatectomy SUI16.
From our experience, good candidates for Ad-
Vance® TOT sling implantation are patients with 
mild to moderate SUI, with preserved residual sphinc-
ter function without scar defects and an adequate 
bladder compliance. Preoperative dynamic urethros-
copy is of the utmost importance to exclude stricture 
disease and to confi rm mobility and coaptive response 
of the membranous urethra during perineal pressure 
test. Midperineal elevation in the lithotomy position 
and the ability to contract external sphincter during 
urethroscopy is a good sign in predicting positive out-
comes after sling placement. If urethral stricture or 
stenosis is present, we advise treating and stabilizing 
this for at least 6 months before making the decision 
regarding sling placement.
In the present study, 47 patients with mild to severe 
SUI after prostatectomy were treated with the Ad-
Vance® sling. Our results of the AdVance® sling sus-
pension with overall success rate of 78.6% (cure rate 
51.1%, improvement rate 27.5%) are comparable to 
previously published follow-up series shown in Table 
39,12,16-19. Moreover, the success rates are comparable to 
success rates for other sling systems20-23. Rehder et al.24 
demonstrated that surgeons in high-volume centers 
may even improve functional results with increasing 
experience. Comparison of outcome rates between dif-
ferent studies is very diffi  cult, because diff erent classi-
fi cations or defi nitions of incontinence, patient selec-
tion criteria and cure rate defi nitions were used. How-
ever, the comparison of outcomes between key studies 
suggests that higher rates of continence can be achieved 
in patients with mild to moderate, rather than severe 
incontinence. Nevertheless, the success rate of 91.7% 
in our study is signifi cant, especially when analysing 
cure and improvement rates following sling placement 
for patients without additional treatments after pros-
tate surgery (cure rate 61.1%, improvement rate 
30.6%).
As expected, success rates after sling placement for 
patients with additional treatments after prostatecto-
my were much lower in our study (40% for radiation 
Table 3. Studies evaluating effi  cacy of the AdVance® sling suspension
Study N of patients
Follow up 





Gozzi et al. (2008)(8) 67 3 No pad use 52 10
Cornu et al. (2009)(9) 102 13 No pad use or one for security reasons 62.7 17.6
Bauer et al. (2009)(12) 70 12 No pads or one dry security pad 51.4 25.7
Rehder et al. (2010)(16) 118 12 No pad use or one for security reasons 73.7 16.9
Cornel et al. (2010)(17) 35 12 No pad use and 24-h pad test <2 g 9 45.5
Cornu et al. (2011)(18) 136 21 No pad use or use only for security reasons 62 16
Berger et al. (2011)(19) 26 22 No pad use 61.5 26.9
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therapy and only 33.3% for internal urethrotomy 
group). Like our study, several authors found a trend 
for an association with previous radiation therapy and 
treatment failure4,5,19,24,25. It seems that cure rates are 
lower for patients who are unable to contract their ex-
ternal sphincter, have a poor response to midperineal 
pressure test during dynamic urethroscopy and those 
with scarred and immobile urethra, i.e. after radiother-
apy or repeated surgery for urethral stricture dis-
ease18,24,25. Both therapies are known to potentially 
cause severe scarring and decrease urethral mobility 
which is of absolute importance, and are, in our opin-
ion, relative contraindications for AdVance® sling 
placement. In any case, these suboptimal candidates 
may experience poorer results than the ideal candidate, 
but they still have a chance to achieve considerable im-
provement.
Complication rates in our study are minimal and 
acceptable, and confi rm fi ndings from previous re-
ports25-27. In contrast to a larger study from Bauer et 
al.25 evaluating complications after AdVance® sling 
implantation with a retention rate of 21.3%, the post-
operative urinary retention rate in our series (2.1%) is 
substantially lower. Two of our patients had local post-
operative wound infection and were treated with oral 
antibiotics.
Our study is not without limitations. Although the 
initial results after AdVance® sling placement are en-
couraging, further long-term follow-up and evaluation 
for much larger series is needed. Postoperative success 
rates can be further improved by better patient selec-
tion criteria, for example by excluding patients with 
severe periurethral fi brosis and scarring due to previ-
ous radiation therapy and surgery for recurrent stric-
ture disease.
Conclusions
Postprostatectomy SUI remains a signifi cant prob-
lem impacting a large number of patients with resul-
tant impairment of quality of life. AdVance® sling is 
the only product on the market which focuses on re-
storing normal anatomy and off ers non-compressive 
functional approach for the treatment of postprosta-
tectomy SUI. Th e results from our study suggest a fa-
vourable success rate (78.6%) with acceptable minor 
complications (6.4%) after AdVance® sling placement 
and are comparable to results from larger series. Our 
experience suggests that cystoscopically confi rmed re-
sidual sphincter function is the most important re-
quirement for a good outcome. Th e most appropriate 
candidates for the placement of the AdVance® sling 
may be those with mild to moderate postoperative 
SUI. Th e results may be even better in patients without 
additional treatment following radical prostatectomy, 
such as radiation therapy or surgery for urethral stric-
ture disease. Patients with urethral immobility, scar-
ring and severe incontinence can be treated, but a real-
istic explanation of the outcomes should be off ered to 
them when making the decision about the treatment.
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Sažetak
TRANSOPTURATORNA ADVANCE® SUSPENZIJA U LIJEČENJU 
POSTOPROSTATEKTOMIJSKE STRESNE INKONTINENCIJE MOKRAĆE
Goran Štimac, Borislav Spajić, Alek Popović, Danijel Justinić, Igor Grubišić, Šoip Šoipi, 
Ivan Svaguša, Matea Pirša i Boris Ružić
Unatoč napretku u liječenju lokaliziranog raka prostate radikalnom prostatektomijom, i dalje je prisutan dio bolesnika 
kod kojih perzistira stresna urinarna inkontinencija (SUI). Suburetralni, a odnedavno i transopturatorni „slingovi“ zbog 
 neinvazivnosti postaju metodom izbora u liječenju ovih bolesnika. U članku prikazujemo kiruršku tehniku i naše rezultate 
liječenja postoperativne SUI metodom AdVance®. Od studenog 2010. do lipnja 2017. metodom AdVance® na Klinici je 
operirano 47 bolesnika. Zabilježena je dob, etiologija i trajanje SUI te dnevni broj uložaka preoperativno i postoperativno. 
Izlječenje je defi nirano kao potpuna kontinencija ili korištenje jednog sigurnosnog uloška / dan. Poboljšanje je defi nirano kao 
korištenje 1-2 uloška / dan te smanjenje u dnevnom broju uložaka veće od 50%. U ispitivanom razdoblju kod operiranih 
bilježimo značajan pad prosječnog broja uložaka / dan s 5.1 (2-8) na postoperativno 1.7 (0-4). Prema našim kriterijima, 
postoperativno je kontinentno 51.1% (24/47), a poboljšanje kontinencije nalazimo kod 27.5% (13/47) operiranih. Kod 78.6% 
(37/47) operiranih broj dnevno korištenih uložaka smanjio se za više od 50% i/ili je kontinentno. Stope neuspjeha znatno su 
veće kod bolesnika koji su nakon prostatektomije tretirani radioterapijom (60% (3/10)) ili uretrotomijom (66.7% (4/10)). 
Rezultati liječenja postoperativne SUI suspenzijom AdVance® u našoj ustanovi usporedivi su s rezultatima do sada objavlje-
nih studija. Suspenzija AdVance® indicirana je kod bolesnika s blagom do umjerenom postoperativnom SUI te očuvanom 
ostatnom funkcijom sfi nktera potvrđenom uretrocistoskopijom. Očekivano, a zbog periuretralne fi broze, uspješnost metode 
upitna je kod bolesnika koji su nakon prostatektomije tretirani radioterapijom ili endourološkim zahvatima.
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